MBS303, a Novel 2:1 CD20xCD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase I , Dose-Escalation Trial
机构：[1]Department of Lymphoma, Peking University Cancer Hospital, BEIJING, China[2]Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China浙江省肿瘤医院[3]Department of Medical Oncology, Afliated Hospital of Hebei University, Baoding, China河北大学附属医院[4]Department of Hematology, The First Afliated Hospital of Ningbo University, Ningbo, China[5]Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China[6]Department of Lymphatic Oncology, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[7]Department of lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China[8]Beijing Mabworks Biotech Co., Ltd., Beijing, Ch
Background: New treatment options are needed for patients (pts) with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL),
especially those with aggressive B-NHL. MBS303 is a CD20×CD3 T-cell-engaging bispecic antibody that has a novel 2:1
(CD20:CD3) conguration to kill malignant B cells. This dose-escalation phase Ⅰ trial evaluated the safety and efcacy of
single-agent MBS303 in pts with R/R NHL (NCT05806).
第一作者机构：[1]Department of Lymphoma, Peking University Cancer Hospital, BEIJING, China
推荐引用方式(GB/T 7714)：
Song Yuqin,Yang Haiyan,Jia Youchao,et al.MBS303, a Novel 2:1 CD20xCD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase I , Dose-Escalation Trial[J].BLOOD.2024,144:6481-6482.doi:10.1182/blood-2024-199342.
APA：
Song, Yuqin,Yang, Haiyan,Jia, Youchao,Sheng, Lixia,Deng, Lijuan...&Li, Feng.(2024).MBS303, a Novel 2:1 CD20xCD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase I , Dose-Escalation Trial.BLOOD,144,
MLA：
Song, Yuqin,et al."MBS303, a Novel 2:1 CD20xCD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase I , Dose-Escalation Trial".BLOOD 144.(2024):6481-6482
医学